Vantage logo

Abbvie looks east for CD47

Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.

Vantage logo

Bristol bets on cytokines again

The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.